Over the past 20 years, clinical research has focused on the development of reperfusion therapies for acute ischemic stroke (AIS), which include the use of systemic intravenous thrombolytics (alteplase, desmoteplase, or tenecteplase), the augmentation of systemic intravenous recanalization with ultrasound, the bridging of intravenous with intra-arterial thrombolysis, the use of multi-modal approaches to reperfusion including thrombectomy and thromboaspiration with different available retrievers. Clinical trials testing these acute reperfusion therapies provided novel insight regarding the comparative safety and efficacy, but also raised new questions and further uncertainty on the field. Intravenous alteplase (tPA) remains the fastest and easiest way to initiate acute stroke reperfusion treatment, and should continue to be the first-line treatment for patients with AIS within 4.5 h from onset. The use of tenecteplase instead of tPA and the augmentation of systemic thrombolysis with ultrasound are both novel therapeutical modalities that may emerge as significant options in AIS treatment. Endovascular treatments for AIS are rapidly evolving due to technological advances in catheter-based interventions and are currently emphasizing speed in order to result in timely restoration of perfusion of still-salvageable, infarcted brain tissue, since delayed recanalization of proximal intracranial occlusions has not been associated with improved clinical outcomes. Comprehensive imaging protocols in AIS may enable better patient selection for endovascular interventions and for testing multi-modal combinatory strategies.

Department of Neurology School of Medicine University of Ioannina Ioannina Greece

Department of Neurology The University of Tennessee Health Science Center Memphis TN USA

Department of Neurology The University of Tennessee Health Science Center Memphis TN USA ; 2nd Department of Neurology School of Medicine University of Athens Attikon University Hospital Athens Greece ; International Clinical Research Center St Anne's University Hospital Brno Czech Republic

Zobrazit více v PubMed

Fisher M. Acute ischemic stroke therapy: current status and future directions. Expert Rev Cardiovasc Ther (2013) 11(9):1097–9.10.1586/14779072.2013.827450 PubMed DOI

Hill MD, Hachinski V. Stroke treatment: time is brain. Lancet (1998) 352(Suppl 3):SIII10–4.10.1016/S0140-6736(98)90088-5 PubMed DOI

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med (1995) 333(24):1581–7.10.1056/NEJM199512143332401 PubMed DOI

Haley EC, Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke (2010) 41(4):707–11.10.1161/STROKEAHA.109.572040 PubMed DOI PMC

Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med (2012) 366(12):1099–107.10.1056/NEJMoa1109842 PubMed DOI

Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2005) 36(1):66–73.10.1161/01.STR.0000149938.08731.2c PubMed DOI

Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2009) 8(2):141–50.10.1016/S1474-4422(08)70267-9 PubMed DOI PMC

Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 351(21):2170–8.10.1056/NEJMoa041175 PubMed DOI

Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol (2009) 66(1):28–38.10.1002/ana.21723 PubMed DOI

Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 368(10):893–903.10.1056/NEJMoa1214300 PubMed DOI PMC

Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA (1999) 282(21):2003–11.10.1001/jama.282.21.2003 PubMed DOI

Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke (2005) 36(7):1432–8.10.1161/01.STR.0000171066.25248.1d PubMed DOI

Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the multi MERCI trial. Stroke (2008) 39(4):1205–12.10.1161/STROKEAHA.107.497115 PubMed DOI

Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke (2009) 40(8):2761–8.10.1161/STROKEAHA.108.544957 PubMed DOI

Tarr R, Hsu D, Kulcsar Z, Bonvin C, Rufenacht D, Alfke K, et al. The post trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. J Neurointerv Surg (2010) 2(4):341–4.10.1136/jnis.2010.002600 PubMed DOI

Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet (2012) 380(9849):1241–9.10.1016/S0140-6736(12)61384-1 PubMed DOI

Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 380(9849):1231–40.10.1016/S0140-6736(12)61299-9 PubMed DOI PMC

Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med (2013) 368(10):914–23.10.1056/NEJMoa1212793 PubMed DOI PMC

Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med (2013) 368(10):904–13.10.1056/NEJMoa1213701 PubMed DOI PMC

Lowe G. The pharmacology of thrombolytic and fibrinogen-depleting agents in the treatment of acute ischaemic stroke. Cerebrovasc Dis (1998) 8(Suppl 1):36–42.10.1159/000047503 PubMed DOI

Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA (2000) 283(18):2395–403.10.1001/jama.283.18.2395 PubMed DOI

Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: a randomised controlled trial. Lancet (2006) 368(9550):1871–8.10.1016/S0140-6736(06)69776-6 PubMed DOI

Hao Z, Liu M, Counsell C, Wardlaw JM, Lin S, Zhao X. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev (2012) 3:CD000091.10.1002/14651858.CD000091.pub2 PubMed DOI PMC

Multicentre Acute Stroke Trial – Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet (1995) 346(8989):1509–14.10.1016/S0140-6736(95)92049-8 PubMed DOI

Multicenter Acute Stroke Trial – Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med (1996) 335(3):145–50.10.1056/NEJM199607183350301 PubMed DOI

Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian streptokinase (ASK) trial study group. JAMA (1996) 276(12):961–6.10.1001/jama.276.12.961 PubMed DOI

Jauch EC, Saver JL, Adams HP, Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke (2013) 44(3):870–947.10.1161/STR.0b013e318284056a PubMed DOI

European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis (2008) 25(5):457–507.10.1159/000131083 PubMed DOI

Lisabeth LD, Brown DL, Morgenstern LB. Barriers to intravenous tissue plasminogen activator for acute stroke therapy in women. Gend Med (2006) 3(4):270–8.10.1016/S1550-8579(06)80215-9 PubMed DOI

Manawadu D, Bodla S, Jarosz J, Keep J, Kalra L. A case-controlled comparison of thrombolysis outcomes between wake-up and known time of onset ischemic stroke patients. Stroke (2013) 44(8):2226–31.10.1161/STROKEAHA.111.000757 PubMed DOI

Manawadu D, Bodla S, Keep J, Jarosz J, Kalra L. An observational study of thrombolysis outcomes in wake-up ischemic stroke patients. Stroke (2013) 44(2):427–31.10.1161/STROKEAHA.112.673145 PubMed DOI

Labiche LA, Malkoff M, Alexandrov AV. Residual flow signals predict complete recanalization in stroke patients treated with TPA. J Neuroimaging (2003) 13(1):28–33.10.1111/j.1552-6569.2003.tb00153.x PubMed DOI

Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke (2007) 38(3):948–54.10.1161/01.STR.0000257304.21967.ba PubMed DOI

Christou I, Felberg RA, Demchuk AM, Burgin WS, Malkoff M, Grotta JC, et al. Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion. J Neuroimaging (2002) 12(2):119–23.10.1111/j.1552-6569.2002.tb00107.x PubMed DOI

Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology (2000) 55(11):1649–55.10.1212/WNL.55.11.1649 PubMed DOI

Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation (2001) 103(24):2897–902.10.1161/01.CIR.103.24.2897 PubMed DOI

Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 363(9411):768–74.10.1016/S0140-6736(04)15692-4 PubMed DOI

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 359(13):1317–29.10.1056/NEJMoa0804656 PubMed DOI

Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 372(9646):1303–9.10.1016/S0140-6736(08)61339-2 PubMed DOI

Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 7(4):299–309.10.1016/S1474-4422(08)70044-9 PubMed DOI

Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke (2007) 38(3):967–73.10.1161/01.STR.0000258112.14918.24 PubMed DOI

Saqqur M, Tsivgoulis G, Molina CA, Demchuk AM, Garami Z, Barreto A, et al. Design of a prospective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO). Int J Stroke (2008) 3(1):66–72.10.1111/j.1747-4949.2008.00167.x PubMed DOI

Balami JS, Chen R, Sutherland BA, Buchan AM. Thrombolytic agents for acute ischaemic stroke treatment: the past, present and future. CNS Neurol Disord Drug Targets (2013) 12(2):145–54.10.2174/18715273113129990057 PubMed DOI

Rother J, Ford GA, Thijs VN. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. Cerebrovasc Dis (2013) 35(4):313–9.10.1159/000348705 PubMed DOI

Martinez-Sanchez P, Diez-Tejedor E, Fuentes B, Ortega-Casarrubios MA, Hacke W. Systemic reperfusion therapy in acute ischemic stroke. Cerebrovasc Dis (2007) 24(Suppl 1):143–52.10.1159/000107390 PubMed DOI

Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J Stroke (2013) 15(2):90–8.10.5853/jos.2013.15.2.90 PubMed DOI PMC

Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol (2014) 261(6):1069–72.10.1007/s00415-013-7102-0 PubMed DOI

Tsivgoulis G, Alleman J, Katsanos AH, Barreto AD, Kohrmann M, Schellinger PD, et al. Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit–risk analysis of clinical trials. Brain Behav (2014).10.1002/brb3.279 PubMed DOI PMC

Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke (2003) 34(2):537–43.10.1161/01.STR.0000049764.49162.76 PubMed DOI

Reddrop C, Moldrich RX, Beart PM, Farso M, Liberatore GT, Howells DW, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke (2005) 36(6):1241–6.10.1161/01.STR.0000166050.84056.48 PubMed DOI

Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood (1993) 81(10):2636–43. PubMed

Kimura M, Iijima S, Kobayashi K, Furuhata H. Evaluation of the thrombolytic effect of tissue-type plasminogen activator with ultrasonic irradiation: in vitro experiment involving assay of the fibrin degradation products from the clot. Biol Pharm Bull (1994) 17(1):126–30.10.1248/bpb.17.126 PubMed DOI

Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin WS, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring. Stroke (2000) 31(3):610–4.10.1161/01.STR.31.3.610 PubMed DOI

Alexandrov AV. Ultrasound enhanced thrombolysis for stroke. Int J Stroke (2006) 1(1):26–9.10.1111/j.1747-4949.2005.00012.x PubMed DOI

Alexandrov AV, Barlinn K. Taboos and opportunities in sonothrombolysis for stroke. Int J Hyperthermia (2012) 28(4):397–404.10.3109/02656736.2012.674621 PubMed DOI

Rubiera M, Alexandrov AV. Sonothrombolysis in the management of acute ischemic stroke. Am J Cardiovasc Drugs (2010) 10(1):5–10.10.2165/11316850-000000000-00000 PubMed DOI

Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke (2010) 41(2):280–7.10.1161/STROKEAHA.109.563304 PubMed DOI

Ricci S, Dinia L, Del Sette M, Anzola P, Mazzoli T, Cenciarelli S, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2012) 10:CD008348.10.1002/14651858.CD008348.pub3 PubMed DOI

Saqqur M, Tsivgoulis G, Nicoli F, Skoloudik D, Sharma VK, Larrue V, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies. J Neuroimaging (2014) 24(3):209–20.10.1111/jon.12026 PubMed DOI

Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke (2005) 36(7):1441–6.10.1161/01.STR.0000170707.86793.1a PubMed DOI

Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Maisterra O, Delgado P, et al. Do bubble characteristics affect recanalization in stroke patients treated with microbubble-enhanced sonothrombolysis? Ultrasound Med Biol (2008) 34(10):1573–7.10.1016/j.ultrasmedbio.2008.02.011 PubMed DOI

Perren F, Loulidi J, Poglia D, Landis T, Sztajzel R. Microbubble potentiated transcranial duplex ultrasound enhances IV thrombolysis in acute stroke. J Thromb Thrombolysis (2008) 25(2):219–23.10.1007/s11239-007-0044-6 PubMed DOI

Alexandrov AV, Mikulik R, Ribo M, Sharma VK, Lao AY, Tsivgoulis G, et al. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke (2008) 39(5):1464–9.10.1161/STROKEAHA.107.505727 PubMed DOI PMC

Alexandrov AV. Ultrasound enhancement of fibrinolysis. Stroke (2009) 40(3 Suppl):S107–10.10.1161/STROKEAHA.108.530931 PubMed DOI

Xie F, Tsutsui JM, Lof J, Unger EC, Johanning J, Culp WC, et al. Effectiveness of lipid microbubbles and ultrasound in declotting thrombosis. Ultrasound Med Biol (2005) 31(7):979–85.10.1016/j.ultrasmedbio.2005.03.008 PubMed DOI

Culp WC, Porter TR, Lowery J, Xie F, Roberson PK, Marky L. Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine. Stroke (2004) 35(10):2407–11.10.1161/01.STR.0000140890.86779.79 PubMed DOI

Sharma VK, Tsivgoulis G, Lao AY, Malkoff MD, Alexandrov AW, Alexandrov AV. Quantification of microspheres appearance in brain vessels: implications for residual flow velocity measurements, dose calculations, and potential drug delivery. Stroke (2008) 39(5):1476–81.10.1161/STROKEAHA.107.501593 PubMed DOI

Barreto AD, Sharma VK, Lao AY, Schellinger PD, Amarenco P, Sierzenski P, et al. Safety and dose-escalation study design of transcranial ultrasound in clinical SONolysis for acute ischemic stroke: the TUCSON trial. Int J Stroke (2009) 4(1):42–8.10.1111/j.1747-4949.2009.00252.x PubMed DOI

Tsivgoulis G, Alexandrov AV, Sloan MA. Advances in transcranial Doppler ultrasonography. Curr Neurol Neurosci Rep (2009) 9(1):46–54.10.1007/s11910-009-0008-7 PubMed DOI

Tsivgoulis G, Culp WC, Alexandrov AV. Ultrasound enhanced thrombolysis in acute arterial ischemia. Ultrasonics (2008) 48(4):303–11.10.1016/j.ultras.2007.11.008 PubMed DOI

Tsivgoulis G, Alexandrov A. Ultrasound-enhanced thrombolysis: from bedside to bench. Stroke (2008) 39(5):1404–5.10.1161/STROKEAHA.107.505594 PubMed DOI

Barreto AD, Alexandrov AV, Shen L, Sisson A, Bursaw AW, Sahota P, et al. CLOTBUST-hands free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke. Stroke (2013) 44(12):3376–81.10.1161/STROKEAHA.113.002713 PubMed DOI

Barlinn K, Barreto AD, Sisson A, Liebeskind DS, Schafer ME, Alleman J, et al. CLOTBUST-hands free: initial safety testing of a novel operator-independent ultrasound device in stroke-free volunteers. Stroke (2013) 44(6):1641–6.10.1161/STROKEAHA.113.001122 PubMed DOI PMC

Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D. Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry (2011) 82(1):14–9.10.1136/jnnp.2009.203174 PubMed DOI

Balami JS, Sutherland BA, Buchan AM. Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. CNS Neurol Disord Drug Targets (2013) 12(2):155–69.10.2174/18715273112119990050 PubMed DOI

del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT investigators. Prolyse in acute cerebral thromboembolism. Stroke (1998) 29(1):4–11.10.1161/01.STR.29.1.4 PubMed DOI

O’Rourke K, Berge E, Walsh CD, Kelly PJ. Percutaneous vascular interventions for acute ischaemic stroke. Cochrane Database Syst Rev (2010) (10):CD007574.10.1002/14651858.CD007574.pub2 PubMed DOI

IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke (2004) 35(4):904–11.10.1161/01.STR.0000121641.77121.98 PubMed DOI

IMS Study Investigators. The interventional management of stroke (IMS) II study. Stroke (2007) 38(7):2127–35.10.1161/STROKEAHA.107.483131 PubMed DOI

Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, et al. Methodology of the interventional management of stroke III trial. Int J Stroke (2008) 3(2):130–7.10.1111/j.1747-4949.2008.00151.x PubMed DOI PMC

Yeatts SD, Martin RH, Coffey CS, Lyden PD, Foster LD, Woolson RF, et al. Challenges of decision making regarding futility in a randomized trial: the interventional management of stroke III experience. Stroke (2014) 45(5):1408–14.10.1161/STROKEAHA.113.003925 PubMed DOI PMC

Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, et al. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the interventional management of stroke III trial. Radiology (2014) 273(1):202–10.10.1148/radiol.14132649 PubMed DOI PMC

Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, et al. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the interventional management of stroke (IMS III) phase 3 trial. Lancet Neurol (2014) 13(6):567–74.10.1016/S1474-4422(14)70066-3 PubMed DOI PMC

Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev (2013) 5:CD000514.10.1002/14651858.CD000514.pub3 PubMed DOI PMC

Becker KJ, Brott TG. Approval of the MERCI clot retriever: a critical view. Stroke (2005) 36(2):400–3.10.1161/01.STR.0000153056.25397.ff PubMed DOI

Bose A, Henkes H, Alfke K, Reith W, Mayer TE, Berlis A, et al. The Penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol (2008) 29(7):1409–13.10.3174/ajnr.A1110 PubMed DOI PMC

Alexandrov AV, Schellinger PD, Saqqur M, Barreto A, Demchuk AM, Ribo M, et al. Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials. Int J Stroke (2011) 6(2):118–22.10.1111/j.1747-4949.2010.00559.x PubMed DOI

Leker RR, Eichel R, Gomori JM, Ramirez de Noriega F, Ben-Hur T, Cohen JE. Stent-based thrombectomy versus intravenous tissue plasminogen activator in patients with acute middle cerebral artery occlusion. Stroke (2012) 43(12):3389–91.10.1161/STROKEAHA.112.673665 PubMed DOI

Koh JS, Lee SJ, Ryu CW, Kim HS. Safety and efficacy of mechanical thrombectomy with solitaire stent retrieval for acute ischemic stroke: a systematic review. Neurointervention (2012) 7(1):1–9.10.5469/neuroint.2012.7.1.1 PubMed DOI PMC

Qureshi AI, Abd-Allah F, Aleu A, Connors JJ, Hanel RA, Hassan AE, et al. Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR rescue, and synthesis expansion trials: a report from the working group of international congress of interventional neurology. J Vasc Interv Neurol (2014) 7(1):56–75. PubMed PMC

Hinduja A. Imaging predictors of outcome following intravenous thrombolysis in acute stroke. Acta Neurol Belg (2014) 114(2):81–6.10.1007/s13760-013-0270-y PubMed DOI

Abilleira S, Cardona P, Ribo M, Millan M, Obach V, Roquer J, et al. Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy. Stroke (2014) 45(4):1046–52.10.1161/STROKEAHA.113.003489 PubMed DOI

Kurre W, Aguilar-Perez M, Niehaus L, Fischer S, Schmid E, Bazner H, et al. Predictors of outcome after mechanical thrombectomy for anterior circulation large vessel occlusion in patients aged ≥80 years. Cerebrovasc Dis (2013) 36(5–6):430–6.10.1159/000356186 PubMed DOI

Kappelhof M, Marquering HA, Berkhemer OA, Majoie CB. Intra-arterial treatment of patients with acute ischemic stroke and internal carotid artery occlusion: a literature review. J Neurointerv Surg (2014).10.1136/neurintsurg-2013-011004 PubMed DOI

Nagel S, Kellert L, Mohlenbruch M, Bosel J, Rohde S, Ringleb P. Improved clinical outcome after acute basilar artery occlusion since the introduction of endovascular thrombectomy devices. Cerebrovasc Dis (2013) 36(5–6):394–400.10.1159/000356185 PubMed DOI

Fesl G, Holtmannspoetter M, Patzig M, Mayer TE, Pfefferkorn T, Brueckmann H, et al. Mechanical thrombectomy in basilar artery thrombosis: technical advances and safety in a 10-year experience. Cardiovasc Intervent Radiol (2014) 37(2):355–61.10.1007/s00270-013-0827-4 PubMed DOI

Ciccone A, del Zoppo GJ. Evolving role of endovascular treatment of acute ischemic stroke. Curr Neurol Neurosci Rep (2014) 14(1):416.10.1007/s11910-013-0416-6 PubMed DOI PMC

Endovascular equipoise shift in a phase III randomized clinical trial of sonothrombolysis for acute ischemic stroke